Notably, blocking the CCL2 receptor, CCR2, has been shown to improve the therapeutic efficacy of PD-1 inhibitors in cancer treatment, suggesting that a combination of anti-PD-1/PD-L1 and CCR2-targeted therapies may provide superior outcomes compared to either treatment alone [27,28] (Figure 2). This evidence concerns the gene CCR2 and cancer.